Fact-checked by Grok 2 weeks ago

Thoracentesis

Thoracentesis, also known as pleural tap, is a minimally invasive in which a needle or small tube () is inserted through the chest wall into the pleural space—the thin cavity between the visceral pleura (lining the lungs) and the parietal pleura (lining the chest wall)—to remove excess or air. It serves both diagnostic purposes, such as analyzing aspirated to identify causes like infection, malignancy, or , and therapeutic purposes, such as relieving symptoms of due to , which impairs lung expansion. The modern procedure was first performed in 1850 and described in 1852, evolving significantly with the introduction of guidance to improve safety.

Overview

Definition and Purpose

Thoracentesis is a procedure involving the of from the , the potential area between the visceral and parietal pleura surrounding the lungs, typically using a needle or small inserted through the chest wall. This intervention addresses , an abnormal accumulation of in this that can impair lung expansion. The primary purposes of thoracentesis are diagnostic and therapeutic. Diagnostically, it allows for the collection and analysis of pleural fluid to determine the underlying , such as , , or , through cytological, biochemical, and microbiological examinations. Therapeutically, it removes excess fluid to alleviate symptoms like dyspnea and chest discomfort by improving re-expansion and respiratory . Thoracentesis is classified into diagnostic and therapeutic types based on the volume of fluid aspirated. Diagnostic thoracentesis involves withdrawing a small sample, usually 50-100 mL, sufficient for analysis without significantly altering intrapleural dynamics. In contrast, therapeutic thoracentesis removes larger volumes, typically up to 1-1.5 L in a single session, to provide symptomatic relief while minimizing risks like reexpansion . The procedure was first systematically described in the , with Morrill Wyman performing it in 1850 and Henry Ingersoll Bowditch popularizing its use for s shortly thereafter. Over time, it has evolved with the incorporation of imaging guidance, such as , to enhance safety and precision in fluid localization.

Relevant Anatomy

The , also known as the , is a thin, bounded by the visceral pleura covering the lungs and the parietal pleura lining the walls, , and . This serous membrane-lined compartment normally contains a small volume of pleural fluid, approximately 10 to 20 mL per side in healthy adults, which serves to lubricate lung movement during respiration and maintain negative . The accumulation of excess fluid in this space, forming a , creates the clinical context for thoracentesis, but the baseline remains critical for procedural safety. Key thoracic landmarks guide safe needle insertion during thoracentesis to access the pleural space while minimizing risks to adjacent structures. The intercostal spaces, located between the 12 pairs of , provide the primary entry points, with the typically targeting the 6th to 8th intercostal spaces where pleural effusions commonly accumulate at the bases due to . Safe insertion sites are generally in the mid-axillary line (for patients) or the posterior mid-scapular line (for seated patients), positioned above the to avoid intra-abdominal puncture; guidance helps identify the diaphragm's dome and the hypoechoic (fluid-filled) areas at the bases. The , comprising the intercostal vein, , and , runs along the inferior border of each within the intercostal space, necessitating needle advancement over the superior aspect of the lower to prevent vascular injury or damage. Anatomical variations can significantly alter these landmarks and increase procedural complexity. In , increased depth may obscure pockets and require for precise localization, potentially shifting the effective insertion depth. , characterized by hyperinflated lungs, elevates the risk of by altering pleural dynamics and lung base positions, demanding heightened caution during . Prior thoracic surgery often leads to pleural adhesions or scarring, which can distort the pleural and intercostal , complicating access and elevating the potential for incomplete drainage or unintended tissue trauma.

Clinical Indications and Contraindications

Indications

Thoracentesis is primarily indicated for diagnostic evaluation of pleural effusions when the underlying is unclear, allowing of characteristics to differentiate between transudative and exudative causes. It is recommended for suspected infections, such as or , where sampling via , culture, or specific tests like aids in pathogen identification. In cases of suspected , cytological of aspirated (typically 25–50 mL) helps confirm primary or metastatic pleural involvement. Therapeutically, thoracentesis provides symptomatic relief by removing fluid from large s that cause dyspnea, , or . For malignant pleural s, large-volume aspiration is suggested if symptoms' relation to the is uncertain, to assess re-expansion and guide further interventions like . It is also used to drain complicated parapneumonic s or empyemas, preventing progression to . Common specific conditions prompting thoracentesis include congestive heart failure, where bilateral transudative effusions require confirmation to distinguish from other causes; with associated parapneumonic effusions, especially if fluid pH is ≤7.2; and post-surgical or traumatic effusions like . Tuberculosis-related effusions in high-prevalence areas warrant sampling for targeted diagnostics. Guidelines from the American Thoracic Society and British Thoracic Society emphasize performing the procedure under guidance for effusions with a pleural depth greater than 10 to ensure and , avoiding smaller collections that may resolve spontaneously. Contraindications, such as , must be weighed against these indications in clinical decision-making.

Contraindications

Thoracentesis has few absolute contraindications, primarily those where the risks significantly outweigh any potential benefits due to high likelihood of severe complications. Active or at the intended puncture site is an absolute , as it heightens the danger of introducing pathogens into the pleural space, potentially leading to or . Relative contraindications are conditions where thoracentesis may still be performed after careful risk-benefit assessment, often with procedural modifications. These include , which elevates the risk of and due to positive pressure dynamics. Small pleural effusions measuring less than 1 cm on imaging pose a relative , as the limited fluid volume increases the chance of lung puncture without therapeutic gain. An uncooperative patient is also relatively contraindicated, as inability to maintain positioning compromises procedural safety and efficacy. Coagulopathy is considered a relative ; however, evidence indicates that thoracentesis is safe without correction in patients with international normalized ratio (INR) greater than 1.5 or platelet count below 50,000/μL, and even up to INR less than 3 or platelets greater than 25,000/μL, without increased hemorrhagic risk. For patients on anticoagulation , adjustments such as holding agents or administering reversal measures are recommended prior to the procedure to address risks, particularly if baseline coagulation parameters approach relative thresholds. Risk assessment plays a crucial role in managing relative contraindications, with real-time imaging strongly recommended to confirm size, location, and accessibility, thereby reducing overall complication rates and allowing safer performance even in borderline cases.

Procedure

Patient Preparation

Prior to undergoing thoracentesis, patients receive a thorough explanation of the , including its purpose, potential benefits such as relief of dyspnea or diagnostic insights from fluid analysis, risks like or bleeding, and alternative options such as observation or other interventions if applicable. is obtained after this discussion, ensuring the patient understands the process and voluntarily agrees, in accordance with institutional protocols and ethical standards. Laboratory evaluation is essential to assess bleeding risk and overall suitability for the procedure. A coagulation profile, including , international normalized ratio (INR), and , is typically performed to identify any , particularly in patients on anticoagulants or with , though routine testing may be omitted in those without a history of bleeding disorders per British Thoracic Society recommendations. A is also obtained to evaluate platelet count and hemoglobin levels, helping to mitigate risks of hemorrhage or exacerbation. Adjustments to medications like blood thinners or antiplatelets may be required based on these results. Imaging plays a critical role in confirming the presence of and selecting the optimal insertion site. Pre-procedure is recommended to visualize fluid location, depth, and relation to anatomical structures like the , reducing complication rates compared to landmark-based approaches. Chest radiography or computed tomography () may be used adjunctively to assess effusion size and underlying lung pathology, with often preferred for real-time guidance due to its portability and lack of radiation. The patient is positioned to facilitate safe access to the pleural space while maintaining comfort and stability. The preferred posture is sitting upright at the edge of the bed or chair, leaning forward with arms and head supported on a tabletop or overbed table, which allows gravity to pool fluid posteriorly in the dependent portion of the chest. For patients unable to sit, a lateral decubitus on the unaffected side or semi-recumbent posture with the arm abducted may be employed, ensuring the target is accessible within the "triangle of safety" (midaxillary line between the fourth to ninth ribs). Local anesthesia is administered to the skin and subcutaneous tissues at the insertion site using lidocaine, starting with a superficial wheal via a 25-gauge needle followed by deeper infiltration with a 22-gauge needle, minimizing discomfort during needle placement. , including , , , and , are continuously monitored throughout preparation and the procedure to detect any immediate adverse responses. Mild sedation, such as with , may be offered for anxious patients but is not routinely required, as most procedures are well-tolerated under alone; supplemental oxygen is provided if is present.

Technique and Equipment

Thoracentesis requires specific equipment to ensure sterility, precision, and safety during the procedure. Essential items include sterile gloves, gown, and drapes; antiseptic solutions such as or ; local anesthetic (e.g., 1% lidocaine) with syringes and 20- to 22-gauge needles for infiltration; an 18- to 20-gauge needle-catheter assembly with a for access; a three-way stopcock; 30- to 50-mL syringes for ; drainage tubing connected to collection bottles or bags; sterile , bandages, and for ; and specimen containers for samples. An machine with a linear and sterile is also critical for guidance. The technique begins with patient positioning in a seated upright or semi-recumbent posture, with the target site typically in the midaxillary or posterior midscapular line to access safe anatomical zones. The skin is sterilized using solution and draped sterilely. is infiltrated subcutaneously and into deeper tissues along the planned insertion tract using incremental injections to minimize discomfort. Under real-time guidance, the 18- to 20-gauge needle is advanced perpendicularly over the superior margin of the rib to avoid the located inferiorly, with continuous visualization confirming entry into the anechoic pleural collection bordered by the . Negative pressure is applied via or stopcock to aspirate , which is collected for diagnostic purposes (typically 20-30 mL) or therapeutic drainage. If larger volumes are needed, a may be advanced over the needle using the for ongoing drainage via tubing. The needle is withdrawn upon completion, and the site is dressed securely. Real-time ultrasound guidance is the preferred method over blind landmark-based techniques, as it allows dynamic visualization of the effusion, lung, and intercostal structures, significantly reducing procedural risks. Studies demonstrate that ultrasound guidance lowers the pneumothorax rate to approximately 1-4%, compared to 12% or higher with blind approaches, by enabling precise needle trajectory and avoiding lung puncture. This modality is particularly beneficial in patients with small or loculated effusions or those in supine positions. For therapeutic thoracentesis, fluid aspiration is limited to 1.5 L to prevent re-expansion , with drainage performed slowly (e.g., over 30-60 minutes) while monitoring for symptoms such as , , or dyspnea. If symptoms arise after removing more than 500 mL, the should be halted.

Post-Procedure Management

Following thoracentesis, patients are typically observed for 2 to 4 hours to monitor , including , , , and , as well as respiratory status for any signs of distress. This monitoring helps detect early complications such as or re-expansion . Initial is recommended immediately after the , with patients advised to avoid strenuous activities, heavy lifting, or vigorous exercise for at least 24 to 48 hours to minimize the risk of bleeding or site irritation. The insertion site should be kept clean and covered with a sterile dressing, which can usually be removed after 24 hours if there is no leakage. Pain at the insertion site, often described as soreness or discomfort, is common and managed with oral analgesics such as acetaminophen or nonsteroidal drugs (NSAIDs), unless contraindicated. Patients may also experience temporary coughing as the lung re-expands, which typically resolves within an hour. Discharge is appropriate once vital signs are stable, there are no new symptoms such as increasing dyspnea or , and the patient can ambulate without difficulty. Prior to leaving, patients receive instructions to watch for warning signs including fever, redness or swelling at the site, excessive bleeding, persistent , or coughing up blood, and to seek immediate medical attention if these occur.

Complications and Risks

Immediate Complications

Immediate complications of thoracentesis encompass adverse events that arise during the procedure or shortly thereafter, typically within minutes to hours, and are primarily related to procedural technique or patient factors. These include , , or vasovagal reactions, and , with overall major complication rates remaining low at approximately 4-6% when guidance is employed. Pneumothorax is the most frequent immediate complication, resulting from inadvertent puncture of the parenchyma allowing air entry into the pleural space. Its incidence ranges from 1% to 6% with real-time guidance, compared to higher rates of up to 20-30% without such . factors include operator inexperience and small volumes, while prevention is effectively achieved through to confirm pleural fluid location and avoid tissue. In cases requiring intervention, placement may be necessary if the is symptomatic or large. Bleeding complications, such as or subcutaneous , are uncommon, occurring in less than 1% of procedures overall. specifically has an incidence of 0.01-0.1%, often due to intercostal vessel laceration, and is more likely in patients with uncorrected or —conditions that represent relative contraindications. Management typically involves monitoring and, rarely, transfusion or surgical intervention for significant hemorrhage. Pain during the procedure is reported in 5-39% of cases and is usually mild, localized to the insertion site, while vasovagal reactions—manifesting as , , or syncope—affect about 0.6-3% of patients. These are managed through patient reassurance, proper positioning (e.g., semi-upright), and, if needed, atropine administration; prophylactic measures like help mitigate discomfort. Re-expansion pulmonary edema is a rare but potentially serious complication, with an incidence of less than 1%, arising from rapid removal of large-volume effusions exceeding 1.5 liters, leading to increased negative and alveolar-capillary disruption. Symptoms include acute , dyspnea, and , often appearing within hours post-procedure. Prevention involves limiting fluid aspiration to 1-1.5 liters per session or monitoring pleural pressures, with supportive care such as sufficient for most mild cases.

Delayed Complications

Delayed complications of thoracentesis encompass issues that manifest hours to days after the procedure, potentially leading to significant morbidity if not promptly addressed. Among these, stands out as a notable , primarily manifesting as or at the puncture site. Post-procedure infections are rare. Clinical signs include fever, chills, increasing , and reaccumulation of , often necessitating antibiotics and possible drainage. Risk factors include poor sterile technique or underlying , though guidance may mitigate introduction of pathogens. Persistent air leak represents another delayed concern, typically arising from a prolonged where air continues to enter the pleural due to incomplete re-expansion or parenchymal . This complication may require insertion of a for ongoing drainage, with symptoms such as persistent dyspnea and developing over days. Although incidence post-thoracentesis ranges from 1% to 6% with guidance (higher without), cases evolving into persistent leaks are less common and often resolve with unless tension develops. Underlying disease, such as , heightens susceptibility. Tumor seeding is a rare but serious delayed complication in patients with malignant pleural effusions, where neoplastic cells are disseminated along the needle tract, potentially leading to subcutaneous or chest wall metastases. This occurs infrequently, with reported rates below 1% for diagnostic thoracentesis, though higher (up to 20%) in more invasive pleural interventions like indwelling catheters. Manifestations include nodular lesions along the tract appearing weeks to months later, emphasizing the need for cautious needle placement in cases. Loculated effusion can form as a delayed , where residual fluid becomes compartmentalized by adhesions or , hindering complete drainage and complicating subsequent procedures. This typically emerges days post-thoracentesis in inflammatory or malignant contexts. Symptoms involve persistent or worsening , often necessitating advanced interventions like fibrinolytics or for resolution. Overall, delayed complications like these contribute to a procedural risk profile of under 5%, per major guidelines, underscoring the procedure's relative safety when performed adeptly.

Follow-up Imaging

Following thoracentesis, a routine chest is typically obtained within 2 hours to evaluate for , a common immediate complication occurring in up to 30% of cases without guidance. This imaging modality provides a quick assessment of lung re-expansion and detects air in the pleural space, guiding further interventions if needed. Although some guidelines suggest limiting routine to symptomatic patients to reduce unnecessary , it remains standard practice in many settings to ensure procedural safety. Further imaging is indicated for patients with persistent symptoms such as dyspnea, chest pain, or cough, where ultrasound or computed tomography (CT) can identify effusion recurrence, loculations, or other issues like complicated parapneumonic effusions. Ultrasound is preferred for its bedside availability and lack of radiation, allowing real-time evaluation of residual fluid or septations, while CT offers detailed characterization of pleural abnormalities in complex cases. These modalities help differentiate between simple reaccumulation and underlying pathology requiring additional management. In chronic pleural effusion cases, serial imaging—such as repeat or chest X-rays—is used to monitor therapeutic outcomes and assess fluid reaccumulation rates, which can occur in 60% of patients within days post-procedure. This approach tracks expandability and informs decisions on repeat thoracentesis or indwelling placement. The American College of Radiology appropriateness criteria recommend CT chest with intravenous contrast as usually appropriate for suspected complicated pleural disease, warranting advanced imaging when initial evaluations suggest , , or loculated effusions. These guidelines emphasize tailored imaging based on clinical suspicion to optimize diagnostic yield while minimizing risks.

Pleural Fluid Analysis

Transudate versus Exudate

In the analysis of pleural fluid obtained via thoracentesis, distinguishing between transudative and exudative effusions is essential for guiding the of underlying conditions. Transudates result from imbalances in hydrostatic and oncotic pressures across the pleural capillaries, leading to of with low protein content and typically clear appearance. Exudates, conversely, arise from increased permeability of the due to local or injury, resulting in fluid rich in proteins and often cloudy or turbid. The standard method for classification is Light's criteria, established in a seminal study, which identifies an exudate if one or more of the following are met: pleural fluid protein divided by serum protein greater than 0.5, pleural fluid (LDH) divided by serum LDH greater than 0.6, or pleural fluid LDH exceeding two-thirds of the upper limit of normal for serum LDH. These thresholds leverage simultaneous serum and pleural fluid measurements to reflect the relative protein and enzymatic content, with transudates generally showing lower values across these parameters. Common causes of transudative effusions include congestive heart failure, which elevates hydrostatic pressure; hepatic cirrhosis with , reducing oncotic pressure; and , characterized by . In contrast, exudative effusions are frequently due to infections such as or , malignancy involving the pleura, and , which provoke inflammatory responses and vascular leakage. Despite its utility, Light's criteria have limitations, including misclassification of up to 25% of transudates as exudates, particularly in patients receiving diuretics for conditions like , where fluid concentration increases without altering the underlying . The criteria demonstrate high (approximately 98%) for detecting exudates but lower specificity (around 83%), potentially necessitating additional tests in ambiguous cases, such as a serum-pleural albumin gradient greater than 1.2 g/dL (or protein gradient >3.1 g/dL), which can reclassify most mislabeled transudates due to congestive or .

Biochemical Markers

Biochemical markers in pleural fluid provide targeted diagnostic insights into specific underlying pathologies once the initial transudate-exudate classification, such as via Light's criteria, has been established. These soluble analytes help differentiate conditions like infections, malignancies, and rare disruptions in thoracic structures, guiding therapeutic decisions without relying on cellular components. Elevated pleural fluid amylase levels, typically exceeding those in serum, are indicative of pancreaticopleural fistula from pancreatitis or pseudocyst rupture, or esophageal perforation. In such cases, amylase concentrations can reach thousands of units per liter, with isoenzyme analysis distinguishing pancreatic (P-type) from salivary (S-type) origins to confirm the source. This marker is particularly useful in unexplained exudative effusions with abdominal symptoms, as pancreatic disease accounts for only about 4.5% of amylase-rich pleural fluids, while malignancy is more common. Low pleural fluid glucose, defined as less than 60 mg/dL (3.3 mmol/L), suggests increased metabolic consumption by inflammatory or neoplastic processes and is commonly seen in rheumatoid arthritis, empyema, or malignancy. Levels below 40 mg/dL (2.2 mmol/L) are especially characteristic of chronic rheumatoid effusions or advanced infections like empyema, often correlating with acidosis and warranting further intervention. This finding is non-specific but, when combined with clinical context, supports aggressive management in parapneumonic cases. Pleural fluid pH below 7.2 signals a complicated progressing to , reflecting bacterial metabolism and tissue that necessitates prompt drainage to prevent loculation. Measured via blood gas analysis for accuracy, such low pH values (often <7.0 in frank ) predict poor outcomes if untreated and outperform glucose alone in prognostic utility. High pleural fluid triglyceride levels greater than 110 mg/dL (1.24 mmol/L), particularly when cholesterol is below 200 mg/dL (5.18 mmol/L), confirm due to thoracic duct disruption, with a milky appearance aiding gross identification. Levels below 50 mg/dL virtually exclude this diagnosis, emphasizing the test's high negative predictive value. In contrast, —a chronic, cholesterol-rich effusion from long-standing inflammation like tuberculosis or rheumatoid disease—features pleural fluid cholesterol exceeding 200 mg/dL (5.18 mmol/L), often with a cholesterol-to-triglyceride ratio greater than 1 and visible cholesterol crystals on microscopy. These effusions lack chylomicrons and typically occur in thickened pleura, distinguishing them from true . Adenosine deaminase (ADA) activity in pleural fluid, elevated above 40 U/L, offers high diagnostic accuracy for tuberculous effusions, with mean sensitivity of 92% and specificity of 90% in endemic areas. This T-cell-derived enzyme reflects lymphocytic immune activation and is particularly valuable in lymphocyte-predominant exudates from resource-limited settings, though false positives can occur in empyema or malignancy. N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in pleural fluid, typically exceeding 1500 pg/mL, are highly useful for identifying effusions due to congestive heart failure, especially those misclassified as exudates by Light's criteria in patients on diuretics. With sensitivity and specificity both exceeding 90%, pleural NT-proBNP outperforms serum levels alone and aids in confirming cardiac etiology without invasive testing.

Cellular and Microbiological Evaluation

Cellular and microbiological evaluation of pleural fluid provides critical insights into inflammatory and infectious etiologies of effusions, guiding targeted therapy. The total white blood cell (WBC) count is a key initial metric; counts exceeding 1000 cells/μL are characteristic of exudative effusions, distinguishing them from transudates with lower cellularity. The differential cell count further refines the diagnosis: neutrophil predominance (>50% of total WBCs) strongly suggests acute bacterial processes, such as parapneumonic effusions, whereas lymphocytic predominance (>50%, and often >80% in tuberculous cases) indicates chronic conditions like . Eosinophil percentages >10% are typically linked to non-infectious causes, including air or blood introduction into the pleural space or drug-induced reactions. Microbiological assessment begins with rapid tests like Gram staining, which identifies bacterial in suspected , though sensitivity is limited, particularly after antibiotic exposure. Routine cultures for aerobic/ , mycobacteria, and fungi are essential; bacterial cultures yield positive results in about 40% of pleural cases, with improved detection (up to 58%) when fluid is inoculated directly into bottles at the bedside. Acid-fast bacilli (AFB) smears and cultures target , but smear positivity is low (<40%), necessitating prolonged incubation for confirmation. For enhanced diagnostic speed, molecular methods such as (PCR) are recommended when or viral pathogens are suspected; these assays on pleural fluid demonstrate high specificity and can expedite identification of . Overall interpretation combines cellular patterns with : for example, neutrophil-dominant effusions with low (<7.2) often signal complicated bacterial infections requiring drainage.

Cytological Examination

Cytological examination of pleural fluid obtained via thoracentesis is a key diagnostic step for detecting malignant cells, particularly in cases of suspected . The process begins with of the fluid sample to concentrate cellular components, typically at speeds around 1,600 rpm for 10 minutes, yielding a for further preparation. This is then used to create smears or cell blocks, which are stained using the to enhance nuclear and cytoplasmic details, facilitating microscopic evaluation for atypical cellular features such as irregular nuclei, prominent nucleoli, and abnormal patterns indicative of . Positive cytological findings confirm the presence of malignant cells, often identifying specific tumor types including , , and metastatic carcinomas from primary sites like the or . The sensitivity of this examination for detecting in pleural effusions is approximately 60%, though it varies by tumor —higher for adenocarcinomas (up to 80%) and lower for mesotheliomas (around 20-30%). These findings provide crucial diagnostic confirmation, guiding subsequent therapeutic decisions such as or . False-negative results occur in up to 40% of cases, primarily due to low tumor cell burden in the , where malignant cells are sparse or absent despite underlying pleural involvement. Repeat thoracentesis can improve diagnostic yield by 10-20% in such scenarios, as subsequent samples may capture exfoliated tumor cells more effectively. To enhance accuracy and enable precise cell typing, adjunct techniques such as and are employed on the cytological material. identifies aberrant immunophenotypes in suspicious cell populations, while uses markers like Ber-EP4 for epithelial cells or for mesothelial differentiation to distinguish malignant from reactive cells. These methods are particularly valuable in borderline cases with atypical cells, increasing overall diagnostic specificity.

References

  1. [1]
    Thoracentesis - StatPearls - NCBI Bookshelf - NIH
    Oct 6, 2024 · Thoracentesis is a critical medical procedure designed to remove fluid or air from the pleural space, serving diagnostic and therapeutic purposes.
  2. [2]
    Thoracentesis: MedlinePlus Medical Encyclopedia
    Aug 19, 2024 · Thoracentesis is a procedure to remove fluid from the space between the lining of the outside of the lungs (pleura) and the wall of the chest.
  3. [3]
    [PDF] Thoracentesis and Thoracic Ultrasound
    Diagnostic thoracentesis is performed to obtain a small volume of fluid (50–100 mL) for the purpose of analysis, which is accomplished with a single ...
  4. [4]
    Large-volume thoracentesis and the risk of reexpansion pulmonary ...
    Background: To avoid reexpansion pulmonary edema (RPE), thoracenteses are often limited to draining no more than 1 L. There are, however, significant clinical ...
  5. [5]
    Thoracentesis, Chest Tubes, and Tunneled Chest Drains - PMC - NIH
    Thoracentesis involves aspiration of the fluid from the pleural space and may be diagnostic and/or therapeutic in nature.
  6. [6]
    Henry Ingersoll Bowditch: The Prominent Physician Who Introduced ...
    Jan 19, 2024 · He had widely used thoracentesis, an ancient procedure, for pleuritic effusions, diagnosed with a stethoscope. Inside his most popular treatise ...
  7. [7]
    Physiology, Pleural Fluid - StatPearls - NCBI Bookshelf
    In a healthy human, the pleural space contains a small amount of fluid (about 10 to 20 mL), with a low protein concentration (less than 1.5 g/dL). Pleural ...Introduction · Issues of Concern · Development · Organ Systems Involved
  8. [8]
    Anatomy, Thoracotomy and the Collateral Intercostal Neurovascular ...
    Sep 26, 2022 · The entry site is classically taught to be just above the superior border of the lower rib. This location can certainly reduce the risk of ...
  9. [9]
    British Thoracic Society Guideline for pleural disease - Thorax
    The guideline focuses on the investigation and management of pleural disease in adults and covers four broad areas of pleural disease.
  10. [10]
    Thoracentesis: Background, Indications, Contraindications
    Sep 11, 2020 · Thoracentesis is indicated for the symptomatic treatment of large pleural effusions (see the images below) or for treatment of empyemas.
  11. [11]
    Management of Malignant Pleural Effusions. An Official ATS/STS ...
    PICO 3: In patients with symptomatic MPE, we suggest large-volume thoracentesis if it is uncertain whether the patient's symptoms are related to the effusion ...
  12. [12]
    The Safety of Thoracentesis in Patients with Uncorrected Bleeding ...
    INR > 1.5 secondary to liver disease or warfarin therapy ... Feller-Kopman D, Berkowitz D, Boiselle P, Ernst A. Large-volume thoracentesis and the risk of ...
  13. [13]
    THORACENTESIS COURSE - Hospital Procedures Consultants
    Absolute Contraindications. – Uncooperative patient – Overlying skin infection – Ruptured diaphragm. Relative Contraindications. – Small pleural effusion (≤ 1 ...Missing: guidelines | Show results with:guidelines
  14. [14]
    How To Do Thoracentesis - Pulmonary Disorders - Merck Manuals
    Contraindications to Thoracentesis. Absolute contraindications: None. Relative contraindications: Bleeding disorder or anticoagulation. Altered chest wall ...
  15. [15]
    Thoracentesis - FPnotebook
    Sep 8, 2025 · Absolute contraindications. INR >3 (on Warfarin); Partial ... Coagulopathy correction prior to Thoracentesis is performed in some guidelines.
  16. [16]
  17. [17]
    Thoracentesis for the Diagnosis and Management of Pleural Effusions
    Dec 8, 2023 · The British Thoracic Society recommends 25–50 mL of pleural fluid for cytologic testing during diagnostic thoracentesis [11]. Utilizing cell ...
  18. [18]
    Thoracentesis: Purpose, Procedure, Risks & Recovery
    Oct 3, 2022 · How do I prepare for a thoracentesis? · Have a blood clotting (bleeding) condition. · Take blood thinners or aspirin. · Take any other prescription ...
  19. [19]
    Thoracentesis for treating pleural effusions - Radiologyinfo.org
    Thoracentesis helps determine the cause of the excess fluid. It also helps ease any shortness of breath or pain by removing the fluid and relieving pressure on ...What Is A Thoracentesis? · How Is The Procedure... · What Will I Experience...Missing: anatomy | Show results with:anatomy
  20. [20]
    Thoracentesis | Sonoguide - ACEP
    Nov 29, 2021 · Ultrasound allows the distinction between effusion and lung consolidations, and the diagnostic accuracy of ultrasound for pleural effusions ...Missing: size | Show results with:size
  21. [21]
    None
    ### Patient Preparation for Pleural Aspiration/Thoracentesis
  22. [22]
    [PDF] Thoracentesis - American Thoracic Society
    To remove this fluid for evaluation (testing) or improve a patient's breathing, a procedure called a thoracentesis is done. Thoracentesis involves placing a ...Missing: indications | Show results with:indications
  23. [23]
    Can ultrasound guidance reduce the risk of pneumothorax following ...
    We sought to determine whether ultrasound-guided thoracentesis can reduce the risk of pneumothorax and improve outcomes (fewer procedures without fluid removal ...<|control11|><|separator|>
  24. [24]
    Post-Thoracentesis Ultrasound versus Chest Radiography for the ...
    Oct 25, 2024 · Ultrasound guidance reduces pneumothorax rate and improves safety of thoracentesis in malignant pleural effusion: report on 445 consecutive ...
  25. [25]
    Re-expansion pulmonary edema following thoracentesis - PMC - NIH
    After we drained 800 mL of fluid via thoracentesis, a repeat chest radiograph showed no change in the size of the effusion. We made a preliminary diagnosis of ...Missing: maximum | Show results with:maximum
  26. [26]
    Thoracentesis | Johns Hopkins Medicine
    Thoracentesis is done to remove the extra fluid when it's causing symptoms, such as trouble breathing. Or it's done to find the cause of a pleural effusion.What Is Thoracentesis? · Why Might I Need... · What Happens During...Missing: anatomy reliable
  27. [27]
    About Your Thoracentesis - Memorial Sloan Kettering Cancer Center
    You may still have fluid leakage for up to 72 hours (3 days) after your procedure. If you don't have leakage, you can take the bandage off in 24 hours. During ...Before Your Procedure · During Your Procedure · After Your ProcedureMissing: guidelines | Show results with:guidelines
  28. [28]
    Complications of thoracentesis: incidence, risk factors, and ... - NIH
    Although thoracentesis is generally considered safe, procedural complications are associated with increased morbidity, mortality, and healthcare costs.
  29. [29]
    Thoracentesis techniques: A literature review - PMC - NIH
    Jan 5, 2024 · Overall, there was a 4.4% complication rate. The majority were minor complications such as chest discomfort, bleeding at the site, and vasovagal ...Missing: immediate | Show results with:immediate
  30. [30]
    Adverse events related to thoracentesis and chest tube insertion
    Jan 2, 2021 · The incidence of pneumothorax due to thoracentesis is reportedly about 0.6–4%, and chest tube complications have been reported most frequently ...
  31. [31]
    Ultrasound guidance reduces pneumothorax rate and improves ...
    The routine use of US guidance during thoracentesis drastically reduces the rate of pneumothorax and tube thoracostomy in oncological patients, thus improving ...Missing: equipment | Show results with:equipment
  32. [32]
    Incidence of bleeding in patients on different anticoagulants ... - NIH
    Jul 19, 2021 · Although coagulation profile is usually evaluated prior to thoracentesis, bleeding is a rare complication, occurring in less than 1% of the cases.
  33. [33]
    Intercostal Artery Laceration: Rare Complication of Thoracentesis ...
    Hemothorax is a fatal but fortunately rare occurrence following thoracentesis. It usually results from laceration of the intercostal artery.Missing: immediate | Show results with:immediate
  34. [34]
    Managing complications of pleural procedures - PMC - NIH
    Pain is reported following thoracentesis in anywhere from 5–39% of patients (5,6,24). In an audit by Hooper et al., 8% reported pain during chest tube ...Missing: immediate | Show results with:immediate
  35. [35]
    Ultrasound-guided thoracentesis: is it a safer method? - PubMed
    Vasovagal reactions occurred in 0.6% despite no administration of prophylactic atropine. Re-expansion pulmonary edema complicated 2 of 373 thoracenteses (0.5%) ...
  36. [36]
    Reexpansion pulmonary edema after therapeutic thoracentesis - PMC
    Pulmonary reexpansion edema may be considered an iatrogenic complication due to rapid emptying of the pleural cavity. The incidence referred is less than 1 ...
  37. [37]
  38. [38]
    Malignant pleural effusions and trapped lung - AME Medical Journal
    A loculated MPE may become secondarily infected, especially following multiple thoracenteses or an IPC placement. VATS decortication of the inflammatory cortex ...
  39. [39]
    Abstract No. 563 Chest Radiograph after Thoracentesis: Is It Always ...
    Thus, we conclude that chest radiograph after thoracentesis may not always be necessary, especially for asymptomatic patients. Clinical relevance: Pneumothorax ...Missing: up imaging
  40. [40]
    Is chest radiography routinely needed after thoracentesis?
    Jun 1, 2019 · No. After thoracentesis, chest radiography or another lung imaging study should be done only if pneumothorax is suspected, if thoracentesis requires more than ...
  41. [41]
    Pleural procedural complications: prevention and management - PMC
    Chest X-ray allows the identification of complications (including ... 2 hours but may be delayed for as long as two days. Predicting which patients are ...
  42. [42]
    Pleural effusion - EMCrit Project
    Jan 10, 2024 · The effusion is usually left-sided and massive, with rapid recurrence following thoracentesis. diagnosis. Serum amylase and lipase often aren ...
  43. [43]
    Workup of Pleural Effusion or Pleural Disease - AC Search
    There is no relevant literature to support the use of MRI chest without IV contrast as the next imaging study following a pleural effusion incidentally detected ...
  44. [44]
    ACR Appropriateness Criteria® Workup of Pleural Effusion or ...
    This document summarizes appropriateness guidelines for imaging in four common clinical scenarios in patients with known or suspected pleural effusion or ...
  45. [45]
    Pleural Effusion - StatPearls - NCBI Bookshelf - NIH
    31 ago 2024 · Diagnosis typically involves imaging studies such as radiography and CT scanning, followed by thoracentesis for fluid analysis.Falta(n): serial | Realizar una búsqueda con lo siguiente:serial
  46. [46]
    Diagnostic Approach to Pleural Effusion in Adults - AAFP
    Apr 1, 2006 · Thoracentesis should be performed in all patients with more than a minimal pleural effusion unless clinically evident heart failure is present.
  47. [47]
    Pleural Effusion - Pulmonary Disorders - Merck Manuals
    May 2, 2024 · Transudative effusions are caused by some combination of increased hydrostatic pressure and decreased plasma oncotic pressure.
  48. [48]
    The Light criteria: the beginning and why they are useful 40 years later
    The Light criteria serve as a good starting point in the separation of transudates from exudates. The Light criteria misclassify about 25% of transudates as ...
  49. [49]
    Biochemical Analysis of Pleural Fluid and Ascites - PMC - NIH
    Pleural fluid pH is the most useful marker of infection although LDH and glucose are also used. Pleural fluid amylase is often measured but, if raised, is more ...
  50. [50]
    Origin of Pleural Fluid Amylase in Esophageal Rupture - ACP Journals
    A patient with esophageal rupture and elevated pleural fluid amylase activity mimicking acute pancreatitis was studied to find the origin of the enzyme.
  51. [51]
    In Defense of Low Glucose Level in Pleural Fluid - CHEST Journal
    The documented causes of effusions with low glucose concentrations in the pleural fluid are (1) empyema, (2) rheumatoid pleurisy, (3) lupus pleuritis, (4) ...
  52. [52]
    Pleural fluid pH: Diagnostic, therapeutic, and prognostic value
    A parapneumonic effusion with a pleural fluid pH below 7.2 indicates an empyema is forming which necessitates chest tube drainage in all patients.
  53. [53]
    Clinical aspects of pleural fluid pH - Acutecaretesting.org
    In a separate study, 22 patients with empyema had a mean pleural fluid pH of 6.83 (range 6.29-7.28) [19]. The observation that the lowest pleural fluid pH is ...
  54. [54]
    Chylothorax Workup: Laboratory Studies, Imaging Studies, Procedures
    May 28, 2024 · A level greater than 110 mg/dL reflects a 99% chance that the fluid is chyle. · A level less than 50 mg/dL reflects only a 5% chance that the ...Missing: threshold | Show results with:threshold<|separator|>
  55. [55]
    Pleural Fluid Characteristics of Chylothorax - PMC - PubMed Central
    Conversely, a triglyceride level less than 50 mg/dL for a pleural effusion virtually excluded the diagnosis of chylothorax. These criteria continue to be used ...
  56. [56]
    Clinical approach and review of causes of a chylothorax
    The clinical definition of a pseudochylothorax is the combination of a milky pleural effusion, pleural cholesterol level greater than 200 mg/dL, pleural ...Missing: threshold | Show results with:threshold<|separator|>
  57. [57]
    Adenosine deaminase for diagnosis of tuberculous pleural effusion
    Mar 26, 2019 · Pleural fluid adenosine deaminase (ADA) is a useful diagnostic test for tuberculous pleural effusion (TPE), but its exact threshold and ...
  58. [58]
    Adenosine Deaminase - Testing.com
    Jan 5, 2021 · This test measures the amount of adenosine deaminase present in pleural fluid in order to help diagnose a tuberculosis infection of the pleurae.At a Glance · What is being tested? · Common Questions
  59. [59]
    Pleural effusion: diagnosis, treatment, and management - PMC
    A total nucleated cell count of 1000/mL is the cutoff value for transudates and exudates. Effusions with total cell counts lower than 1000/mL are transudates, ...
  60. [60]
    Diagnostic Tools of Pleural Effusion - PMC - PubMed Central - NIH
    In patients with exudative pleural effusions, the differential cell counts provide clues for the etiology of pleural effusions. Exudative pleural effusions with ...
  61. [61]
    Interpreting pleural fluid results - PMC - NIH
    In healthy individuals, the pleural cavity contains approximately 0.3 mL/kg of fluid. A pleural effusion occurs either when production exceeds reabsorption ...Missing: volume | Show results with:volume
  62. [62]
    Real-time polymerase chain reaction for microbiological diagnosis ...
    The aim of this study was to determine whether using real-time polymerase chain reaction of pleural fluids to identify the causative organism improves the ...
  63. [63]
    Pleural fluid pH: diagnostic, therapeutic, and prognostic value
    A parapneumonic effusion with a pleural fluid pH below 7.2 indicates an empyema is forming which necessitates chest tube drainage in all patients.
  64. [64]
    A comparative diagnostic yield among cytologic examination, cell ...
    Oct 31, 2024 · For the examination of cell blocks, pleural fluid was centrifuged at 1,600 rpm for 10 minutes. Afterward, the supernatant was re-centrifuged at ...
  65. [65]
    Utility of cell block to detect malignancy in fluid cytology
    Conventional smears were prepared from the centrifuged deposit and stained with Leishman-Giemsa and Papanicolaou stain in combination for better categorization ...
  66. [66]
    Malignant pleural effusion diagnosis and therapy - PMC
    Feb 28, 2023 · The sensitivity of a pleural fluid cytology sample taken in the first thoracentesis for the diagnosis of malignancy is 60%, with an increased ...
  67. [67]
    Clinical Impact and Reliability of Pleural Fluid Mesothelin in ...
    Nov 28, 2008 · Although pleural fluid cytology is effective in identifying adenocarcinomas, it has low sensitivity (∼20%) in diagnosing mesothelioma, as ...<|control11|><|separator|>
  68. [68]
    [PDF] Cytology of Pleural Effusions - JournalAgent
    [1] The type of the tumor, tumor burden, and the effusion volume are the cytology determinants of the diagnosis.[5-7] Moreover, a hemorrhagic appearance.
  69. [69]
    Sensitivity of Initial Thoracentesis for Malignant Pleural Effusion ...
    Jul 17, 2018 · The diagnostic yield for malignancy by analysis of pleural fluid cytology obtained on initial thoracentesis is 40–60%, and the yield increases ...Abstract · Introduction · Materials and Methods · Results
  70. [70]
    Simplified Flow Cytometric Immunophenotyping Procedure for the ...
    We developed and validated a simple, rapid, 3-color flow cytometric panel using the adhesion molecule Ber-EP4 to detect epithelial cells in effusions.
  71. [71]
    Immunocytochemistry of effusions: Processing and commonly used ...
    Jan 31, 2022 · The studies concluded that dual staining facilitated easy identification of the foreign populations of malignant cells in effusion fluids.